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inclusion criteria and were excluded from the analysis. A further patient, who was initially included, was subsequently withdrawn from the study protocol by his family physician before receiving any treatment. Of the remaining 148 patients, 75 were allocated to the ketorolac group and 73 to the morphine group.
Study design
The study was a single-centre, prospective, double blind, randomised controlled trial. Patients were randomised between groups using a random numbers table.
A nurse would open a pre-coded envelope indicating details of randomisation number and coded medication. Patients were followed up for up to four weeks following discharge. Those patients with adverse events were encouraged to report these to the study institution within this period. There was no loss to follow up.
Analysis of effectiveness
The analysis of effectiveness was based on intention to treat. The primary health outcome used in the analysis was the degree of pain relief, at rest and with activity, measured using a pain relief score, and any adverse events associated with pain relief. At baseline analysis both patient groups had similar demographic and clinical characteristics.
Effectiveness results
The effectiveness results were as follows:
Using a hazard ratio where scores greater than 1 favoured ketorolac, at rest pain relief was better in patients receiving morphine, although these results were not statistically significant. For a 50% reduction in pain the hazard ratio was 0.83, (95% CI: 0.60 -1.15), for 75% reduction 0.84, (95% CI: 0.60 -1.16), and for 100% reduction 0.93, (95% CI: 0.66 -1.30).
With activity, pain relief was favourable to the ketorolac group, for a 50% reduction the hazard ratio was 1.18, (95% CI: 0.85 -1.63), not significant, for a 75% reduction this ratio was significant 1.49, (95% CI: 1.05 -2.12), (p<0.027).
The median rate of decrease in pain was greater with ketorolac than with morphine, for activity in a period of over onehour, this difference was significant.
The rate of adverse events was significantly different between the two groups; 4 (5%) of the ketorolac group experienced adverse events compared with 65 (89%) of the morphine group, (p<0.0001).
Clinical conclusions
Ketorolac appears to be as efficacious as morphine and may offer an advantage over morphine during activity. It also causes fewer adverse events. Morphine may, however, offer a small clinical advantage over ketorolac for patients at rest.
Measure of benefits used in the economic analysis
The authors did not introduce a summary benefit measure in the economic analysis. As such a cost-consequences analysis was performed.
Direct costs
Costs measured included drug use, pharmacy time, nursing time for both preparation and administration of pain relief, and the treatment of adverse events in the emergency department, emergency room physician costs, inpatient ward costs and re-attendance costs. Costing was undertaken from the perspective of the study institution. A research nurse also recorded procedure times. Resources used in the analysis were reported separately from costs. The costs of drugs used in the analysis were taken from the hospital formulary; a study nurse recorded quantity of drug use. Hospital salary costs were used to estimate costs of nurses, emergency room physicians, pharmacist and dispenser costs. Inpatient ward hours would have had an impact on the results of this study. Patient groups were shown to be comparable at analysis. Appropriate statistical analyses were conducted to take account of potential biases in the analysis. In the economic analysis several health outcomes were included and, therefore, this was a cost-consequences study.
Validity of estimate of costs
All categories of cost relevant to the perspective adopted appear to have been included in the analysis. The estimate of costs was detailed, although the costs of ordering, delivering and controlling drug stock were not included in the analysis, as it proved impossible to identify costs specific to ketorolac and morphine acquisition. Average staff salaries used in the costing analysis may not reflect the actual staff mix at the study institution. The authors noted that their analysis did not deal with the potential benefits for cost-effectiveness resulting from reduced staff contact time with patients, due to the complex nature of these interactions. The sensitivity analysis demonstrated that these omissions are unlikely to affect the authors' conclusions. Costs and quantities were reported separately. Resource use data was also taken from the clinical trial. The dates to which prices relate in the analysis do not appear to have been reported.
Other issues
This was a well-reported study. The authors did make appropriate comparison of the results of their study with those from other publications and the issue of generalisability to other settings was addressed. The authors did not present their results selectively.
